Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979675 | 0.81 | OPRM1 (0.40) | KMT2AHSD11B1CYP3A4CYP2C9OPRL1 | |
| SCHEMBL740951 | 0.77 | KMT2A (0.44) | KMT2AHSD11B1CYP3A4OPRL1MAPT | |
| SCHEMBL741948 | 0.73 | KMT2A (0.43) | KMT2AHSD11B1CYP3A4CYP2C9OPRL1 | |
| SCHEMBL739249 | 0.73 | KMT2A (0.43) | KMT2AHSD11B1CYP3A4CYP2C9OPRL1 | |
| SCHEMBL762151 | 0.73 | KMT2A (0.41) | KMT2AHSD11B1CYP3A4CYP2C9OPRL1 | |
| SCHEMBL15099815 | 0.71 | HSD11B1 (0.42) | KMT2AHSD11B1OPRL1OPRM1OPRD1 | |
| SCHEMBL739714 | 0.71 | HSD11B1 (0.42) | KMT2AHSD11B1OPRL1OPRM1OPRD1 | |
| SCHEMBL4772735 | 0.70 | KMT2A (0.39) | KMT2AHSD11B1OPRL1MAPTMETAP2 | |
| SCHEMBL769095 | 0.69 | HSD11B1 (0.43) | KMT2AHSD11B1OPRL1OPRM1OPRD1 | |
| SCHEMBL14671520 | 0.67 | KMT2A (0.41) | KMT2AHSD11B1OPRL1MAPTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138352-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8003666-B2 | Hydrate for medical purposes | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7928232-B2 | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144339-A1 | METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND | ACSL3, NQO2, COASY | KMT2A 2544/4885HSD11B1 769/4885CYP3A4 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.